EHA 2017 | Reducing the risks of chemotherapy in IGHV-mutated CLL
Philip Thompson, MD, from The University of Texas MD Anderson Center, Houston, TX, details the identification of patients with chronic lymphocytic leukemia (CLL) carrying an IGHV mutation, and the favourable prognosis of this subset of patients who have been treated with an FCR regimen. The potential of pursuing chemotherapy-based strategies and enhancing this through the addition of rituximab and ibrutinib to the regimen in treating IGHV-mutated CLL, with the aim of reducing the long-term risks of chemotherapy, is also covered in this segment. He concludes by stating that his team’s studies in this field have succeeded their expectations and he hopes that positive results in this new treatment regimen for treating IGHV-mutated CLL will be achieved in the future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
